TABLE 2.
Average daily weight gains for the period from vaccination to prior to inoculation with PRRSV, the period after PRRSV challenge, and the entire period from vaccination to necropsy
| Group | ADG fora:
|
||
|---|---|---|---|
| ADG 1 | ADG 2 | ADG 3 | |
| Control | 774.9 ± 28.8 | 1,277.4 ± 33.3A | 875.4 ± 29.1A |
| NV-PRRSV | 793.2 ± 36.1 | 388.2 ± 108.0B | 694.9 ± 36.1B |
| V-PRRSVb | 813.5 ± 23.6 | 783.3 ± 47.9C | 807.5 ± 20.8AB |
| PCV2-V-PRRSVb | 715.0 ± 34.0 | 711.0 ± 37.2C | 714.2 ± 31.0B |
| PCV2 | 732.2 ± 38.8 | 1,099.3 ± 32.3AD | 805.6 ± 33.1AB |
| PCV2-Vb | 739.6 ± 26.8 | 1,044.3 ± 41.1D | 800.6 ± 22.5AB |
| Vb | 797.3 ± 36.5 | 1,138.2 ± 46.8AD | 865.5 ± 35.2A |
a
ADG, average daily weight gain (group means [g] ± standard errors); ADG 1, period from vaccination to prior to inoculation with PRRSV; ADG 2, period after PRRSV challenge; ADG 3, the entire period from vaccination to necropsy. Values within a column with no common superscript are significantly (P < 0.0001) different.
b
Vaccinated with Ingelvac PRRS ATP MLV vaccine (Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO).